| Lisdexamfetamine dimesylate is a stimulant used to treat children, adolescents and adults with attention-deficit/hyperactivity disorder. |
| SPD489-404 was a 2-year safety study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder in which cognitive function was assessed using the Cambridge Neuropsychological Test Automated Battery (CANTAB). |
| In this study, lisdexamfetamine dimesylate treatment was not found to be associated with cognitive impairment; possible improvements in some domains of cognitive function were observed. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.